Humira Rivals Finally Flood Market After 'Patent Thicket' Saga
Biosimilar versions of AbbVie's Humira are finally hitting the U.S. market after AbbVie successfully used a controversial "patent thicket" to shut down competition to the blockbuster immunosuppressant for years, a strategy...To view the full article, register now.
Already a subscriber? Click here to view full article